.svg)
Evidation is a two-sided platform connecting individuals and enterprises. On the consumer side, we provide value to over 4 million individuals across the US who are highly motivated to participate in research including testing of digital health programs. On the enterprise side, Evidation provides biopharma, med-tech, big tech, academic institutions, professional societies, and government partners the ability to: generate evidence; and design, test, and deploy programs that motivate evidence-based action.
Evidation is a two-sided platform connecting individuals and enterprises. On the consumer side, we provide value to over 4 million individuals across the US who are highly motivated to participate in research including testing of digital health programs. On the enterprise side, Evidation provides biopharma, med-tech, big tech, academic institutions, professional societies, and government partners the ability to: generate evidence; and design, test, and deploy programs that motivate evidence-based action.
Evidation runs programs for enterprises to get actionable evidence in three areas: disease burden and patient impact, patient segmentation and identification, disease event and progression modelling. We deploy a proven approach, incorporating our experience with over 200 research programs, to reliably delivers results. Given our connectivity with highly engaged individuals, we deliver faster and more cost-effectively.
Evidation conducted the first study to assess the everyday impact of constipation, a commonly overlooked condition. Through our network of individuals, our team recruited over 1,500 participants with lower gut health issues and had high compliance rates with an intensive 12-week study protocol. In under one year, we delivered results which have the potential to get more patients on the right treatment faster.
Using PGHD, we could identify patients whose asthma symptoms were not adequately managed on current treatments. In one week, Evidation recruited over 14,000 individuals with asthma via our Achievement population and delivered results in under 12 weeks. For two patients below who appear identical in claims data – the same diagnosis (moderate-to-severe asthma) and treatment (LABA/ICS) – with PGHD, we can identify that one patient’s asthma is not suitably controlled on existing treatment. Similarly, we see clear splits in activity sleep behaviors that may indicate how well controlled a patient’s asthma is. These findings enable early identification of individuals with inadequate symptom control, who could benefit from treatment.
Through PGHD, Evidation detected and measured the impact of flares in an autoimmune condition. We were able to detect flares through measured changes in behavior and quantify flare impact and recovery over time. This foundation has the potential to help accelerate time to diagnosis and getting patients on the right treatment faster.
Our product enables enterprises to design, test, and deploy digital programs to motivate individuals to engage in their health, in a measurable way. Evidation offers enterprises subscription-based access to specific cohorts—for example individuals managing heart conditions such as heart failure, dyslipidemia, hypertension, atrial fibrillation—to validate how to engage the right individuals and motivate the right action at the right time.
Our platform allows enterprises to identify the right individuals, engage to drive insight generation, and measure the results.
Identify the right patients
Using signals from devices, data from apps, and PROs
EXAMPLE: Individuals with worsening symptoms, such as a HF patient with sudden weight gain
Engage on the right action
Applying test-and-learn approach, building on behavior nudging theory
EXAMPLE: Prompts to read materials to manage symptoms, alerts to engage clinician when weight spikes exceed guidelines
Measure action and outcome
Enabling continuous improvement and proving return on investments
EXAMPLE: Engagement measure (retention, clicks), action measure (outreach to clinician, report taken to clinician)
For Sanofi, Evidation identified 30,000 individuals with type 2 diabetes, at high-risk for the flu. We engaged this population in a variety of ways to obtain the flu vaccine, resulting in a measurable increase in vaccination rates relative to those we did not engage.
Further reading
Evidation is working with J&J and Apple to improve diagnosis/treatment rates and outcomes for atrial fibrillation. We identify at-risk individuals, engage through tailored insights, and provide tools to support better conversations with clinicians to get appropriate care sooner.
Further reading...
